5 qualities to seek in your cell therapy supply chain vendor

As your cell or gene therapy operations scale from early-phase clinical trials to larger populations in late-stage trials and commercialization, your supply chain complexity — and risk — increases. Anticipating common setbacks and actively planning for their solution requires a specialized and collaborative approach with your supply chain partner. Keep these key considerations top of…

Depiction of international autologous cell therapy logistics.

Overcoming autologous cell therapy logistics challenges in the age of COVID-19

There is no question the COVID-19 pandemic has disrupted cell therapy logistics like never before. Supply chain challenges are no longer the exception, but the norm. So how can companies overcome autologous cell therapy logistics challenges to deliver time-sensitive source material and manufactured therapies on time? It’s not easy in our current environment, but it…

Representation of cell therapy production disruption due to COVID-19 pandemic

How COVID-19 is changing the production of cell therapies

This piece written by Joy Aho, PhD, Senior Product Manager, Be The Match BioTherapies®, was originally published on CellandGene.com in April 2020. We’re living through unprecedented times, both as individuals and as a nascent cell therapy field. The COVID-19 pandemic has had negative implications for manufacturing and shipping across nearly all industries, including very pronounced…

Representation of NMDP/Be The Match donor collection network

Managing donor collections during the COVID-19 pandemic

Even before COVID-19 reached pandemic levels, teams at the National Marrow Donor Program® (NMDP)/Be The Match® had their eye on an important part of the cell therapy supply chain—donor collections. Collections from allogeneic donors are critical to getting time-sensitive life-saving cell therapies to patients around the world. But donors often must fly to the apheresis…

COVID-19

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Updated March 27, 2020 (original story follows) Editor’s note: It’s been just over one month since we first shared how established relationships have helped our organization navigate the impacts of the coronavirus on the cell therapy supply chain. Since then, much has changed. Just a few days after we posted the story, reports from Italy…

HLA matching could bring more allogeneic cell therapies to market, faster

The emergence of novel cell therapy technologies has led to questions about the necessity of human leukocyte antigen matching (HLA matching) in the development of potential “universal” allogeneic cell therapies. After all, if you can eliminate alloreactive responses, what role would HLA matching play? Martin Maiers, MS, is the Vice President of Biomedical Informatics for…